Stem cell injections are not a proven replacement for hip replacement surgery. A 2024 review found only 10 hip-specific studies involving 316 patients. Some studies reported less pain and better function, but reliable cartilage regrowth and long-term avoidance of surgery have not been proven. For advanced hip arthritis, total hip replacement has a much larger and more mature evidence base.[1]
A stem cell injection keeps the existing hip joint in place. Hip replacement does something very different: it removes damaged joint surfaces and replaces them. That difference matters. The amount of structural damage, pain, and loss of function should drive the discussion.
What Hip Arthritis Actually Damages
Hip osteoarthritis can wear away cartilage, narrow the joint space, create bone spurs, change the bone beneath the cartilage, and gradually reduce hip movement.
Typical symptoms include pain in the groin or thigh, stiffness after sitting, shorter walking distance, trouble with stairs, and difficulty putting on shoes or getting into a car. Night pain and pain at rest usually mean the condition is interfering more heavily with daily life.
Not every painful hip has osteoarthritis. Osteonecrosis, inflammatory arthritis, lumbar spine problems, and tendon disorders can feel similar. The diagnosis needs to be clear before comparing injections with surgery.
The same basic rule applies across regenerative medicine: evidence from one disease, cell source, or delivery method cannot automatically be carried over to another.
What Is Actually Injected?
“Stem cell injection” sounds like one treatment. It is not.
Research and clinical programs may use:
- bone marrow aspirate
- bone marrow aspirate concentrate
- adipose-derived preparations
- stromal vascular fraction
- culture-expanded mesenchymal stromal cells
These products can differ in cell source, cell number, processing method, viability, dose, and number of injections.
The American College of Rheumatology and Arthritis Foundation strongly recommends against routine stem cell injections for hip and knee osteoarthritis because the products and techniques are highly variable and poorly standardized.[2]
What Does the Hip-Specific Research Show?
A 2024 systematic review found 10 studies involving 316 patients who received mesenchymal stem or stromal cell approaches for hip osteoarthritis. Individual studies ranged from just 1 patient to 147. Cell sources, doses, outcomes, and follow-up periods were all different.[1]
Several studies reported less pain or better function. Most of the evidence, though, came from small observational studies and case series rather than large randomized trials.[1]
There is no dependable overall success rate from this evidence.
How Much Pain Relief Has Been Reported?
One retrospective study followed 31 patients aged 32 to 83 after an intra-articular bone marrow aspirate injection.
At 6 months, 42% reported at least a 50% reduction in pain. At 12 months, the figure was 61%.[3]
The results looked very different when patients were separated by osteoarthritis grade:
- 80% of 10 grade 2 patients reached at least 50% pain reduction at 12 months.
- 71% of 14 grade 3 patients reached that threshold.
- 14% of 7 grade 4 patients reached it.
The study was small, retrospective, and had no randomized control group. Bone marrow aspirate also contains many cell types and biological components. It is not a standardized purified stem cell product.[3]
So those percentages should not be advertised as general success rates. At most, they suggest that people with advanced arthritis may respond differently from people with earlier disease.
Does Pain Relief Mean Cartilage Has Regrown?
No. Feeling better and rebuilding cartilage are separate outcomes.
An injection may reduce inflammation or pain without replacing lost cartilage. In advanced hip arthritis, there may already be severe cartilage loss, very narrow joint space, bone spurs, bone remodeling, and changes in joint shape.
Current human evidence does not show that stem cell injections reliably reverse those structural changes.[1]
Claims such as “rebuilds the hip,” “reverses bone-on-bone arthritis,” or “guarantees cartilage regrowth” go further than the evidence allows.
Can Stem Cell Injections Delay Hip Replacement?
This has not been proven.
A patient might feel better for 6 or 12 months and still need hip replacement later. To prove that an injection truly delays surgery, researchers would need controlled studies that follow patients for several years and measure the actual time to hip replacement.
Those studies would also need to track pain, walking ability, imaging, repeat injections, and adverse events. The current hip-specific evidence is too small and too mixed to answer the question reliably.[1]
What Do Major Medical Guidelines Say?
The American College of Rheumatology and Arthritis Foundation strongly recommends against stem cell injections for hip and knee osteoarthritis because current products and techniques are not standardized.[2]
NICE describes intra-articular stem cell treatment for osteoarthritis as experimental and does not support routine use outside research.[4]
The U.S. FDA states that regenerative medicine therapies have not been approved for orthopedic conditions such as osteoarthritis or hip pain.[5]
Already have a hip diagnosis or recent imaging?
Prepare your X-ray or MRI, diagnosis, current medicines, previous injections, and physical therapy history. These records make it much easier to work out which treatment questions actually apply to your stage of disease.
Stem Cell Injection vs. Hip Replacement
| Question | Stem Cell Injection | Total Hip Replacement |
|---|---|---|
| Main goal | Investigational symptom or biological improvement | Replace damaged joint surfaces |
| Damaged joint surfaces removed | No | Yes |
| Reliable cartilage regrowth proven | No | Not its purpose |
| Established treatment for end-stage hip OA | No | Yes |
| Hip-specific evidence | Small, mixed studies | Large clinical studies and national registries |
| Long-term durability data | Not established | Decades of follow-up available |
| Procedure burden | Injection and, in some protocols, cell or tissue harvesting | Major surgery plus postoperative rehabilitation |
| Main uncertainty | Who responds, by how much, and for how long | Individual complication and revision risk |
How Long Does a Modern Hip Replacement Last?
A 2026 systematic review and registry meta-analysis included 1,904,237 total hip replacements: 5,203 procedures from 29 clinical studies and 1,899,034 from eight national joint registries.
For contemporary implants, estimated survival was 93.6% at 20 years. Projected survival was 92.8% at 25 years and 92.1% at 30 years.[6]
The 25- and 30-year figures are projections. “Implant survival” means revision surgery was not required. It does not mean every patient stayed completely pain-free.
What About Younger Patients?
A systematic review covering 3,219 hip replacements in patients younger than 55 found average implant survival of 98.7% at 5 years and 94.6% at 10 years. Mean Harris Hip Score improved from 43.6/100 before surgery to 91.0/100 after surgery.[7]
Only 27% of procedures in that review were for osteoarthritis. Other diagnoses included avascular necrosis and developmental dysplasia. Those numbers should not be treated as a personal prediction for every younger patient with OA.[7]
What Are the Main Risks of Hip Replacement?
Possible complications include infection, dislocation, fracture, blood clots, nerve injury, implant loosening, and the need for revision surgery later.
In the under-55 systematic review, average reported rates were 2.4% for dislocation and 1.2% for deep infection.[7]
Personal risk changes with age, smoking, diabetes, bone quality, previous surgery, and other medical problems.
When Should Surgery Be Discussed?
NICE recommends considering referral for joint replacement when pain, stiffness, reduced function, or progressive deformity has a major effect on quality of life and nonsurgical treatment is no longer effective or suitable.[8]
In everyday life, that may look like:
- pain waking you at night
- pain while resting
- steadily shorter walking distance
- difficulty using stairs
- difficulty putting on shoes or socks
- progressive loss of hip movement
- daily activities staying limited despite nonsurgical treatment
Seeing a surgeon does not mean you have agreed to surgery. It gives you a clearer picture of the joint damage, likely benefit, and your own surgical risk.
What Can Be Tried Before Surgery?
Exercise and physical therapy: AAOS states that physical therapy can improve pain and function in selected people with mild to moderate symptomatic hip osteoarthritis. Common goals include hip and gluteal strength, mobility, and walking capacity.[9]
NSAIDs: Oral nonsteroidal anti-inflammatory drugs have strong evidence for symptom relief in hip OA when medically appropriate. Kidney disease, gastrointestinal bleeding risk, cardiovascular disease, and drug interactions can make regular use unsuitable.[9]
Corticosteroid injection: AAOS supports short-term symptom improvement in selected patients. NICE notes that relief is usually short-lived, around 2 to 10 weeks.[9][8]
Image guidance: The ACR/Arthritis Foundation strongly recommends image guidance for intra-articular hip injections because the hip joint sits deep inside the body.[2]
Hyaluronic acid: AAOS strongly recommends against intra-articular hyaluronic acid for symptomatic hip OA because trials have not shown better pain or functional outcomes than placebo.[9]
PRP: The ACR/Arthritis Foundation strongly recommends against PRP for hip and knee OA because preparations vary widely and the evidence remains uncertain.[2]
Knee evidence cannot simply be copied over to the hip. The site’s review of knee osteoarthritis and regenerative medicine covers that separate evidence base.
Who Might Still Discuss an Investigational Stem Cell Treatment?
No major guideline has defined an ideal candidate for hip stem cell treatment.
Before discussing an investigational injection, check whether:
- hip osteoarthritis has actually been confirmed
- other causes of pain have been excluded
- standard nonsurgical treatment has already been reviewed
- the exact cell preparation is known
- the regulatory pathway is clear
- the published evidence involved patients with similar disease severity
- the treatment goal is clearly defined as pain, function, imaging change, or another endpoint
Suitability can also change with medical history, disease stage, cell source, and administration method. The site’s guide to stem cell therapy indications and contraindications in Japan explains the main screening factors.
Are Stem Cell Injections FDA-Approved for Hip Arthritis?
No regenerative medicine therapy is currently FDA-approved to treat orthopedic conditions such as osteoarthritis or hip pain.[5]
“FDA registered,” “processed in an FDA-registered facility,” and “FDA approved for hip osteoarthritis” are three different claims. Only the last one would mean the regulator approved that specific treatment for that specific condition.
How Is the Regulatory Situation Different in Japan?
Japan has its own regulatory framework for regenerative medicine.
Treatment provided under Japan’s regenerative medicine framework is not the same as PMDA marketing approval for a specific regenerative medical product.[10]
PMDA lists approved regenerative medical products one by one, with defined products and indications.[11]
Before travelling for treatment, ask for the exact treatment name, cell source, whether the cells are autologous or donor-derived, processing method, dose, number of administrations, and regulatory pathway.
The stem cell treatment process in Japan explains the records and treatment details worth confirming before you book.
Get the exact treatment protocol before paying or booking travel.
Ask for the cell source, processing method, dose, number of sessions, regulatory pathway, total cost, and follow-up plan in writing. “Stem cell treatment” on its own is too vague to compare evidence or risk.
What Are the Risks of Stem Cell Injections?
Possible risks include pain, bleeding, infection, inflammatory reactions, injury to nearby structures, and complications from bone marrow or fat harvesting.
Processing adds other possible problems, such as contamination, poor cell viability, or uncertainty about what the final product actually contains.
The FDA has reported serious adverse events linked to unapproved regenerative products, including infections, neurological events, and tumor formation. Those reports involve different products and diseases, so they cannot be turned into a specific complication rate for hip injections.[5]
Autologous treatment is not risk-free. Tissue collection, processing, and injection are still medical procedures.
How Should Cost Be Compared?
Compare the price of the full treatment course, not just one injection.
Ask whether the quote includes consultation, imaging review, blood tests, tissue collection, processing, every planned injection, medicines, and follow-up.
The stem cell treatment cost guide explains why two prices cannot really be compared until you know the cell source and treatment schedule.
Questions to Ask Before a Hip Stem Cell Injection
What exactly will be injected?
Ask for the cell source, processing method, dose, and administration route.
Was the same preparation tested in published studies?
Evidence for culture-expanded bone marrow MSCs does not validate a different adipose-derived or donor product.
Were the studies performed in hip osteoarthritis?
Evidence from knee OA does not establish efficacy in the hip.
How severe was the arthritis in the study population?
Small studies suggest that response may differ by disease stage, but current sample sizes are too small for dependable stage-specific success rates.
Was there a randomized control group?
Without a control group, improvement from baseline may reflect the treatment, natural symptom fluctuation, expectations, or other care.
What outcome is being measured?
Pain relief, walking ability, MRI changes, cartilage regrowth, and avoiding surgery are separate outcomes.
How long were patients followed?
Feeling better at 6 or 12 months does not prove several years of disease modification.
How many patients later needed hip replacement?
Ask this directly if the treatment is being sold as an alternative to surgery.
What happens if the first treatment fails?
Ask how many repeat treatments may be suggested, what they cost, and when treatment should stop.
Red Flags to Watch For
- “100% success rate”
- “permanent cure for arthritis”
- “guaranteed cartilage regrowth”
- “reverses bone-on-bone arthritis”
- “zero risk”
- “one injection prevents hip replacement”
- “FDA-approved stem cell treatment for hip arthritis”
Current hip-specific evidence is far too small and too varied to support universal guarantees like these.[1]
How to Choose the Next Step
Mild symptoms: start with exercise, strength, mobility, and appropriate symptom control.
Persistent mild-to-moderate symptoms: confirm the diagnosis and disease stage before comparing injection options. Then ask whether the exact preparation being offered has supporting evidence.
Severe daily pain, night pain, or worsening walking ability: get an orthopedic surgical opinion. Advanced mechanical joint damage should not be assumed to respond to an injection.
Considering stem cells mainly to avoid surgery: ask for data showing how many patients later needed hip replacement, not just short-term pain scores.
Finally
Stem cell injections may reduce pain or improve function in some people with hip osteoarthritis, but they are not a proven replacement for hip replacement surgery. Current hip-specific studies are small and do not prove reliable cartilage regrowth or long-term avoidance of surgery. For advanced arthritis, modern hip replacement has much stronger long-term evidence, including about 93.6% implant survival at 20 years.[1][6]
Where treatment is provided
GINZA NOA CLINIC, Ginza, Tokyo
This article was written and medically reviewed at GINZA NOA CLINIC. The photographs below were taken inside the clinic in Chuo-ku, Tokyo.
Royal Crystal Ginza 3F, 5-4-6 Ginza, Chuo-ku, Tokyo 104-0061
3 min from Tokyo Metro Ginza Station (Exit B6); 5 min from JR Yurakucho Station
In-house CPC, facility number FC3250034
WhatsApp +81-8070161366 · LINE +81-8075357788
Medically reviewed by Ryosuke Tanabe, MD (Director, GINZA NOA CLINIC) with Kotaro Yoshimura, MD, PhD (Professor of Plastic Surgery, Jichi Medical University) as technical advisor. Last reviewed 30 September 2026. Every treatment carries risks — ask what they mean for your case at the consultation. Registration and credentials · How we review content